Spineway SA (ALSPW.PA) • EURONEXT
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold ALSPW.PA in your mock portfolio yet.
With EPS of €0.01 and a PE ratio of ~15, Spineway SA appears modestly profitable, but the absolute earnings base is very small and vulnerable to volatility. The valuation multiple is roughly in line with a mature, low‑growth profile rather than a high‑growth medtech story. In the absence of clear revenue growth data or margin expansion, the current financial picture looks fragile but not outright distressed.
The stock trades at €0.15, exactly in line with its 200‑day moving average, signaling a lack of clear long‑term trend or momentum. A 6.3% decline over the last month points to recent selling pressure and weak short‑term sentiment. Without signs of a technical rebound (e.g., price moving decisively above the 200‑day average or oversold RSI), the setup leans negative.
Alternative data show limited digital reach and stagnant or slightly declining engagement. Website traffic is modest at ~5.7k visitors per month, and social media followings are small and either flat or contracting. Zero job openings suggest no visible near‑term expansion, which, combined with soft online traction, points to a lack of growth momentum.
Spineway SA shows marginal profitability but on a very small earnings base, with the stock trading flat to its long‑term average and experiencing recent downside. Alternative data suggest limited growth momentum, weak digital presence, and no clear expansion signals. Overall, the risk/reward profile currently skews to the downside unless the company can demonstrate stronger growth or operational leverage.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get Started